INVESTORS
We operate with trust and do the right thing
News
-
APR 8 2025NewsSubcutaneous Form of Rybrevant in Combination with Leclaza Approved in Europe
-
MAR 28 2025NewsLeclaza-Rybrevant Combination Therapy Approved in Japan
-
MAR 26 2025News[BioTalkTalk] Interview with Dr. John (Jongsung) Koh, Key Developer of Leclaza at Genosco
-
FEB 17 2025NewsOscotec and Genosco Pursue Differentiated Growth Through Independent Research Strategies
-
DEC 31 2024NewsLeclaza Receives European Approval
-
AUG 20 2024NewsLazertinib With Amivantamab Approved by FDA for Use in NSCLC
-
DEC 22 2023NewsFDA Considers First-Line Amivantamab Plus Lazertinib in EGFR+ NSCLC
-
JUN 30 2023NewsYuhan's Leclaza indication expanded as 1st-line NSCLC treatment
-
DEC 1 2022NewsYuhan’s Leclaza records 20.6-month mPFS as 1st-line NSCLC therapy
